

# Marck Bio plant gets Malaysian approval

PRESS TRUST OF INDIA

NEW DELHI, APRIL 16

AHMEDABAD-BASED Marck Biosciences today said its manufacturing unit at Kheda in Gujarat has got approval from Malaysia's National Pharmaceutical Control Bureau (NPCB), paving way for its foray into the country and Singapore.

The approval is for large volume parenterals (LVP) (medicine given intravenously), small volume parenterals (SVP) and ophthalmics, the company said in a statement.

"The NPCB approval has significant implications for Marck. Our early entry into Malaysia and Singapore opens up a large export market for our products," Marck Biosciences Managing Director Bhavesh Patel said.

Since the NPCB is a participant of the Pharmaceutical Inspection Convention and Pharmaceutical Inspection Co-operation Scheme (PIC/S), which has 36 participating authorities, including those from the United Kingdom and Australia, the approval will help Marck's registration endeavors in other PIC/S member countries, he added.

"With the NPCB approval and the most modern SVP and large volume parenterals capacity at our Kheda facility, we will efficiently cater to Malaysia, Singapore and Brunei with our vast product range. A strong marketing, sales and distribution team will be put in force by our South East Asia Head to accelerate the penetration planned," Patel said.

Marck Biosciences products are marketed in over 70 countries across Latin America, Asia, Africa, Asia Pacific countries.